NL-OMON38302招募中不适用
Blood-brain barrier permeability and cerebral perfusion in Alzheimer*s disease - Vascular dysfunction in AD
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients with AD:
- •Informed consent before participation in the study
- •Received standard diagnostic procedure according to the Parelsnoer Initiative procedure
- •Diagnosed with dementia of the Alzheimer*s type
- •Clinical dementia rating (CDR) of 1, which means a mild to moderate stage of dementia
- •MMSE >= 20 and patients are mentally competent This inclusion criterion is conform the Parelsnoer Initiative inclusion criteria. By the Parelsnoer Initiative, individuals with an MMSE >=18 are considered mentally competent.;Patients with prodromal AD:
- •Informed consent before participation in the study
- •Received standard diagnostic procedure according to the Parelsnoer Initiative procedure
- •Diagnosis of prodromal dementia according to the Dubois criteria (16)
- •CDR of 0.5, which suggests a very mild stage of dementia
- •Memory impairment defined as Delayed Recall on Verbal Learning Test (15 WLT) <1.5 SD
- •MMSE >= 20 and patients are mentally competent.
- •Medial temporal lobe atrophy scale MTA >= 1 (17) OR abnormal levels of Aß42, t-tau or p-tau;Healthy participants:
- •Informed consent before participation in the study
- •No Diagnosis of dementia, prodromal dementia, or mild cognitive impairment.
- •MMSE >= 26
- •No substantial memory complaints (according to participant ánd partner/relative)
- •Age, gender and education is matched to the patient groups.
排除标准
- •Contraindications for scanning (e.g. brain surgery, cardiac pacemaker, metal implants, claustrophobia, large body tattoos)
- •Contraindications for contrast agent Gadovist (renal failure) as determined by the estimated Glomular Filtration Rate eGFR < 30 mL/min.
- •Major vascular disorders (e.g. stroke, heart disease)
- •Psychiatric or neurological disorders (e.g. Major depression; history of schizophrenia; bipolar disorder; psychotic disorder NOS or treatment for a psychotic disorder; cognive impairment due to alcohol abuse; epilepsy, Parkinson*s disease, MS, brain surgery, brain trauma, electroshock therapy, kidney dialysis, Meniere*s disease, brain infections)
- •Structural abnormalities of the brain
- •Cognitive impairment due to alcohol/drug abuse
- •Absence of reliable informant (for AD patient groups)
研究者
相似试验
招募中
不适用
Quantitative blood-brain barrier permeability and susceptibility mapping for patients with CADASIL and suspected to have CADASICADASIJPRN-UMIN000035081agoya City University40
进行中（未招募）
Unknown
Permeability of the blood-brain barrier in Alzheimer’s diseaseISRCTN17419165niversity of Southampton70
招募中
不适用
Blood brain barrier permeability and inflammatory biomarkers in patients with depressioF32.2F32.3F33.2F33.3Severe depressive episode without psychotic symptomsSevere depressive episode with psychotic symptomsRecurrent depressive disorder, current episode severe without psychotic symptomsRecurrent depressive disorder, current episode severe with psychotic symptomsDRKS00022091Klinik für Psychiatrie, Psychosomatik und PsychotherapieUniversitätsklinikum Frankfurt100
进行中（未招募）
不适用
Studies on Permeability of the Blood-Brain-Barrier for Escitaloprame related to various Genotypes of the ABCB1-Gene: Effects on Sleep and Motoric Learning - Escitaloprame, sleep, blood-brain-barrierEffects on sleep electroencephalogram and motoric learning in healthy volunteers related to the permeability of the blood-brain-barrier related to genotypes of the ABCB 1 geneEUCTR2006-001491-21-DEMax Planck Institute of Psychiatry58
已完成
不适用
Blood-Brain Barrier permeability quantification in cerebral small vessel disease -- reproducibility of dynamic contrast-enhanced MRICerebral small vessel diseasedisease of the small brain arteries10007963NL-OMON38519Medisch Universitair Ziekenhuis Maastricht20